WinSanTorâs mission is simple-develop a drug that works. We recognize that there are no treatments for this disease today. Thus, WinSanTor is striving to impact the lives of todayâs patients heavily burdened by peripheral neuropathy. We are impatient. We are exploiting every strategy, mechanism, and regulation to accelerate approval of our drugs, including recycling a previously approved safe drug. Phase 1 is complete and we are now starting phase 2. Our goal is to get drug approval in the US by 2021 and perhaps sooner elsewhere. By focusing on patient impact rather than the bottom line, we believe weâre creating a new sustainable model for pharma companies based on patient need, not just money. Source
No articles found.
Dynatronics is a leading medical device company committed to providing high-qualit...
Dynatronics is a leading medical device company...
DarioHealth Corp. (NASDAQ: DRIO) is a leading global Digital Therapeutics (DTx) co...
DarioHealth Corp. (NASDAQ: DRIO) is a leading g...
Entera Bio is a clinical-stage biopharmaceutical company focused on the developmen...
Entera Bio is a clinical-stage biopharmaceutica...
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on...
Deciphera Pharmaceuticals is a clinical-stage b...
We are an international biotechnology company that is focused in the field of rege...
We are an international biotechnology company t...
We are a clinical stage biopharmaceutical company focused on the discovery, develo...
We are a clinical stage biopharmaceutical compa...
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical...
Neurocrine Biosciences (Nasdaq: NBIX) is a neur...
Join the National Investor Network and get the latest information with your interests in mind.